Skip to main content
    C

    Cumberland Pharmaceuticals Inc (CPIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.21
    -0.67 (-11.39%)

    Market Cap: $88.16M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Cumberland Pharmaceuticals Inc (CPIX) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cumberland Pharmaceuticals (CPIX) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Cumberland Pharmaceuticals reported EPS of -$0.07. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    63%(12/19)
    Avg Surprise
    +89.29%

    Next Report

    CPIX has an expected report date of Mar 1, 2027.

    CPIX Earnings Call

    The latest CPIX earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 19 quarters below that had an estimate, CPIX beat 12, missed 4 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $2.16M, up 1157.1% from $171821 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.07N/AN/AN/AN/AN/AN/AN/ANov 10, 2026$2.16M
    Jun 30, 2026-$0.20N/AN/AN/AN/AN/AN/AN/AAug 4, 2026$166458
    Mar 31, 2026-$0.22N/AN/AN/AN/A-366.9%N/AN/AMay 5, 2026$9.13M
    Dec 31, 2025-$0.09N/AN/AN/AN/AN/AN/AN/AMar 3, 2026$13.68M
    Sep 30, 2025-$0.13N/AN/AN/AN/AN/AN/AN/ANov 4, 2025$171821
    Jun 30, 2025-$0.05N/AN/AN/AN/AN/AN/AN/AAug 5, 2025$380797
    Mar 31, 2025$0.08N/AN/AN/AN/AN/AN/AN/AMay 6, 2025$11.71M
    Dec 31, 2024-$0.14N/AN/AN/AN/AN/AN/AN/AMar 4, 2025$10.44M
    Sep 30, 2024-$0.11N/AN/AN/AN/A-649.5%N/AN/ANov 7, 2024$9.09M
    Jun 30, 2024-$0.08N/AN/AN/AN/A-148.1%N/AN/AAug 6, 2024$9.85M
    Mar 31, 2024-$0.14N/AN/AN/AN/A-225.5%N/AN/AMay 7, 2024$8.50M
    Dec 31, 2023-$0.44N/AN/AN/AN/AN/AN/AN/AMar 5, 2024$9.35M
    Sep 30, 2023$0.02N/AN/AN/AN/AN/AN/AN/ANov 7, 2023$10.09M
    Jun 30, 2023$0.16N/AN/AN/AN/AN/AN/AN/AAug 8, 2023$10.89M
    Mar 31, 2023$0.11N/AN/AN/AN/AN/AN/AN/AMay 9, 2023$9.22M
    Dec 31, 2022-$0.05N/AN/AN/AN/AN/AN/AN/AMar 7, 2023$9.12M
    Sep 30, 2022-$0.03-$0.03N/A0.00%In lineN/AN/AN/ANov 8, 2022$11.41M
    Jun 30, 2022-$0.09-$0.09N/A0.00%In line-212.5%N/AN/AAug 9, 2022$10.30M
    Mar 31, 2022-$0.09-$0.09N/A0.00%In line-228.6%N/AN/AMay 10, 2022$11.18M
    Dec 31, 2021-$0.26-$0.01N/AN/AN/A-2700.0%N/AN/AMar 8, 2022$8.32M
    Sep 30, 2021-$0.07-$0.11N/A+36.36%Beat-450.0%N/A0 up, 1 downNov 9, 2021$8.07M
    Jun 30, 2021$0.08-$0.07-$0.07 - -$0.07+214.29%Beat0.0%1N/AAug 10, 2021$9.06M
    Mar 31, 2021$0.07-$0.07-$0.07 - -$0.07+200.00%Beat+600.0%1N/AMay 11, 2021$10.54M
    Dec 31, 2020$0.01-$0.01-$0.01 - -$0.01+200.00%Beat-88.9%1N/AMar 9, 2021$10.26M
    Sep 30, 2020$0.02-$0.07-$0.07 - -$0.07+128.57%Beat+100.0%1N/ANov 10, 2020$9.25M
    Jun 30, 2020$0.08$0.03$0.03 - $0.03+166.67%Beat-20.0%1N/AAug 11, 2020$9.60M
    Mar 31, 2020$0.01$0.02$0.02 - $0.02-50.00%Miss-90.9%1N/AMay 20, 2020$8.33M
    Dec 31, 2019$0.09$0.01$0.01 - $0.01+800.00%Beat-10.0%1N/AMar 18, 2020$9.31M
    Sep 30, 2019$0.01$0.11$0.11 - $0.11-90.91%MissN/A1N/ANov 12, 2019$6.94M
    Jun 30, 2019$0.10$0.07$0.07 - $0.07+42.86%Beat+900.0%1N/AAug 14, 2019$9.42M
    Mar 31, 2019$0.11-$0.11-$0.11 - -$0.11+200.00%BeatN/A1N/AMay 14, 2019$8.73M
    Dec 31, 2018$0.10-$0.16-$0.16 - -$0.16+162.50%BeatN/A1N/AFeb 26, 2019$2.10M
    Sep 30, 2018-$0.05-$0.19N/A+73.68%BeatN/AN/AN/ANov 13, 2018$8.49M
    Jun 30, 2018$0.01-$0.08-$0.08 - -$0.08+112.50%BeatN/A1N/AAug 14, 2018$10.16M
    Mar 31, 2018-$0.09-$0.02-$0.02 - -$0.02-350.00%Miss-550.0%1N/AMay 8, 2018$8.59M
    Dec 31, 2017-$0.05-$0.02N/A-150.00%MissN/AN/AN/AMar 6, 2018$11.65M
    Sep 30, 2017-$0.05N/AN/AN/AN/A-881.3%N/AN/ANov 7, 2017$11.20M
    Jun 30, 2017-$0.32N/AN/AN/AN/AN/AN/AN/AAug 8, 2017$8.67M
    Mar 31, 2017$0.02N/AN/AN/AN/AN/AN/AN/AMay 15, 2017$9.64M
    Dec 31, 2016-$0.05N/AN/AN/AN/A-615.6%N/AN/AMar 7, 2017$9.08M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.19, after -$0.46 the year before. It was -$0.06 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.19N/A
    Dec 31, 2024-$0.46N/A
    Dec 31, 2023-$0.15N/A
    Dec 31, 2022-$0.26N/A
    Dec 31, 2021-$0.18-250.0%
    Dec 31, 2020$0.12-61.3%
    Dec 31, 2019$0.31N/A
    Dec 31, 2018-$0.03N/A
    Dec 31, 2017-$0.40N/A
    Dec 31, 2016-$0.06N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,800 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20262,7635
    2025Q3Sep 30, 20253,4665
    2025Q2Jun 30, 20252,6695
    2025Q1Mar 31, 20253,2845
    2024Q4Dec 31, 20243,6485
    2024Q3Sep 30, 20243,9655
    2024Q2Jun 30, 20243,3995

    2026Q1 Earnings Call

    Opening remarks

    Emily Kent Communications, Dalton Agency Hello, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its first quarter financial results. The release also provided an overall company update, including key developments during the quarter. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. During today's call, management will share an overview of those financial results and a company update, including recent developments and a discussion of Cumberland's brands, pipeline and partners. Participating in today's call are A.J. Kazimi, Cumberland's Chief Executive Officer; Todd Anthony, Vice President, Organizational Development; and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland's annual report on Form 10-K and any subsequent updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations. So information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland's marketed brands. Full prescribing and safety information for each brand is included on the individual product website, and you can find links to those sites on the corporate site at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the financial tables of the earnings release that I noted was issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we will be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call if you prefer. With that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J. Kazimi.

    A.J. Kazimi Chief Executive Officer Well, thank you, Emily, and good afternoon, everyone. We appreciate you joining us today. As Emily mentioned, we'll provide a review of our financial results for the first quarter of 2026. We'll discuss key developments during the period, but we'll also share recent updates.

    Frequently Asked Questions About CPIX

    When is Cumberland Pharmaceuticals's next earnings date?

    Cumberland Pharmaceuticals's next earnings report is expected for Mar 1, 2027.

    How often does CPIX beat earnings estimates?

    Cumberland Pharmaceuticals beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +97.40%.